Edition:
United Kingdom

Nippon Kayaku Co Ltd (4272.T)

4272.T on Tokyo Stock Exchange

1,297JPY
19 Jun 2019
Change (% chg)

¥7 (+0.54%)
Prev Close
¥1,290
Open
¥1,300
Day's High
¥1,314
Day's Low
¥1,291
Volume
671,600
Avg. Vol
462,923
52-wk High
¥1,509
52-wk Low
¥1,143

Latest Key Developments (Source: Significant Developments)

Chugai Pharmaceutical says waiver of claims in patent infringement lawsuit
Wednesday, 11 Apr 2018 

April 11 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it has decided to waive its claim in a patent infringement lawsuit against Nippon Kayaku Co Ltd <<<4272.T>>>.Says co filed a lawsuit to the Tokyo District Court on Aug. 17, 2017, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 monoclonal antibody Herceptin® Injection 60 and 150 (Herceptin® Injection) against Nippon Kayaku, the applicant for marketing approval of the biosimilar of Herceptin® Injection, citing such party's infringement of the application patents for the treatment of breast cancer owned by Genentech Inc.  Full Article

Nippon Kayaku initiates phase II clinical trials on NK105 for treatment of breast cancer
Wednesday, 21 Feb 2018 

Feb 21 (Reuters) - Nippon Kayaku Co Ltd <4272.T>:Says it initiated phase II clinical trials on NK105 for treatment of breast cancer .  Full Article

Nippon Kayaku unit acquires 100 pct stake in RaySpec
Wednesday, 27 Dec 2017 

Dec 27(Reuters) - Nippon Kayaku Co Ltd <4272.T>:Says its consolidated subsidiary Polatechno Co Ltd <<<4239.T>>> acquired 100 percent stake in the United Kingdom-based firm RaySpec Limited, on Dec. 26.  Full Article

Chugai Pharmaceutical says lawsuit on patent infringement concerning Herceptin® injection and petition for provisional disposition order
Friday, 8 Sep 2017 

Sept 8 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says co has filed a lawsuit and a petition for provisional disposition order against Nippon Kayaku Co.,Ltd <<<4272.T>>>, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 monoclonal antibody Herceptin® injection 60 and 150 (Herceptin® injection) .Genentech Inc, a U.S.-based firm, is a patent holder and co is the exclusive licensee of Herceptin® injection .Says co and Genentech are the co-plaintiff of the lawsuit.  Full Article